;

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Finance > Drugmaker Indivior's finance chief Preblick to step down

Finance

Drugmaker Indivior's finance chief Preblick to step down

Published by Global Banking and Finance Review

Posted on December 17, 2024

Featured image for article about Finance

(Reuters) - Indivior said on Tuesday its finance chief Ryan Preblick will step down as the British drugmaker makes changes to its board following pressure from no.2 shareholder Oaktree Capital.

The maker of opioid addiction treatment Sublocade also appointed Robert Schriesheim and Joe Ciaffoni as independent non-executive directors, and said it has agreed to move towards a more standard U.S. system of remuneration for directors following its recent primary listing in New York.

(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)

More from Finance

Explore more articles in the Finance category

Italy's Meloni says it's still 'premature' to sign EU-Mercosur trade deal

Russian attack on Ukraine's Zaporizhzhia injures 26, governor says

UK stocks rebound on banking gains ahead of BoE rate cut call

Decline in UK industrial orders eases slightly, CBI says

Serco sees profit ahead of market view through 2026; CFO to retire next year

Analysis-Crypto investors show caution, shift to new strategies after crash

Growth in UK house prices and private rents slows

Continental picks tyre veteran as CEO to focus on core business

Italy's Meloni says using frozen Russian assets for Ukraine 'far from easy' ahead of EU summit

UK removes duplicate entries from sanctions lists, designations remain in place

Paris' Louvre reopens partially but staff vote to extend strike

Portugal's government to amend labour reform after general strike

View All Finance Posts